ClinicalTrials.gg
CompletedNCT00464737SP888Updated Jun 22, 2015Results posted

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

A Phase 2 interventional study of Rotigotine and Rotigotine in Fibromyalgia Syndrome, sponsored by UCB Pharma. Completed at 35 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
70th of 320
230 · median 72
Started
2007
with 16 others
Phase 2
44 of 369
2 open now
Registered
60th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 70th largest by enrollment of the 320 interventional ones that give a count, is one of 17 that started in 2007, is one of 44 in phase 2, and was the 60th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed.

Read the detailed description

The overall post-Baseline duration of treatment was 13 weeks. The trial consisted of a 4-week Titration Phase, an 8-week Maintenance Phase, a 1-week De-escalation Phase, and a 2-week Safety Follow-Up Phase. If subjects met the eligibility criteria, they were randomized to receive rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or placebo during the Maintenance Phase. During the 4-week Titration Phase, subjects assigned to rotigotine were titrated at weekly intervals of 2 mg/24 hrs until they reached 4 mg/24 hrs or 8 mg/24 hrs. All subjects who completed the 4-week Titration Phase entered an 8-week Maintenance Phase and were maintained at their randomized dose (rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or placebo). No dose adjustment was allowed during the Maintenance Phase. The Treatment Phase was defined as the combined Titration and Maintenance Phases.

03

Conditions studied

  • Fibromyalgia Syndrome

Browse trials for

Keywords

  • Fibromyalgia Syndrome
  • Rotigotine
  • Neupro
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, 18 to 65 years of age (inclusive)
  • Subject fulfills all 3 points of the American College of Rheumatology (ACR) definition for diagnosis of fibromyalgia (pain, stiffness, and/or sleep disorder)
  • Subject must complete an adequate for excluded medications, as necessary, prior to beginning the Baseline Diary Phase
  • Subject has at least moderate pain that is defined as an average pain intensity of ≥5 on an 11-point Likert pain scale (0-10) during the 7 days prior to Baseline
  • Subject must have at least 5 morning and 5 evening Likert pain scale scores for the 7 days immediately prior to Visit 2 and the average daily pain score over these 7 days must be ≥5 (average daily pain score is determined as follows: calculate the mean of the morning and evening scores separately using all pain scores for the 7 days immediately prior to Visit 2; add the mean morning and evening scores and divide by 2)
  • Subject has a score of ≥50 on Fibromyalgia Impact Questionnaire (FIQ), with a score of 100 representing severe disease at Baseline

Exclusion criteria

Exclusion Criteria:

  • Subject has symptomatic regional or structural rheumatic disease (eg, knee or hip osteoarthritis, bursitis, tendonitis), rheumatic disease or inflammatory rheumatic disease, such as systemic lupus erythematosus (SLE), mild primary osteoarthritis of the hand(s) is allowed
  • Subject has diagnosed neuropathic pain syndrome
  • Subject has received therapy with a dopamine agonist (eg, pramipexole, ropinirole) for 3 months or longer that was not considered effective in managing fibromyalgia symptoms
  • Subject is receiving disability or is involved in litigation related to fibromyalgia syndrome
  • Subject has significant psychopathology as determined by the investigator based on results of the Structural Clinical Interview for Diagnosis (SCID-I). The SCID-I must be administered by a physician or clinical psychologist trained to administer the instrument
  • Subject has evidence of an impulse control disorder according to the Jay Modified Minnesota Impulsive Disorders Interview (MIDI)
  • Subject has any medical condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this trial
  • Subject has orthostatic hypotension with a decrease of blood pressure (BP) from supine to standing position of ≥20 mmHg in systolic blood pressure (SBP) or of ≥10 mmHg in diastolic blood pressure (DBP) taken from the 5-minute supine value and the 1- and/or 3-minute standing measurements, or supine SBP \<105 mmHg at Baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

  • Experimental
    Rotigotine 4 mg

    4 mg/24 hrs

    Drug: Rotigotine

  • Experimental
    Rotigotine 8 mg

    8 mg/24 hrs

    Drug: Rotigotine

Interventions

  • Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)

    Also known as: Neupro

  • Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)

    Also known as: Neupro

  • OtherPlacebo

    Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)

    The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).

    Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase

  2. Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)

    The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).

    Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase

Secondary outcomes

  1. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase

    The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  2. Change From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase

    Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  3. Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase

    Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)

    Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase

  4. Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase

    General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)

    Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase

  5. Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase

    The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse \[score of 1\] to much better \[score of 7\]).

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  6. Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase

    An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).

    Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase

  7. Number of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase

    Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.

    Time frame: 12-week Treatment Phase

  8. Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12

    Time frame: End of the Maintenance Phase/Week 12

  9. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase

    The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  10. Change From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase

    All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  11. Change From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase

    The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.

    Time frame: Baseline, Last assessment in the 12-week Treatment Phase

  12. Number of Subjects With Presence of Impulse Control Disorders

    Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).

    Time frame: 12-week Treatment Phase

07

Results

Posted Jan 5, 2010

Participant flow

The Full Analysis Set (FAS) contains all randomized subjects who received at least 1 dose of trial medication, and had at least 1 post-Baseline Likert pain score. The Per Protocol Set contains all subjects in the FAS who completed at least 2 weeks of the Maintenance Phase and had no major protocol deviations.

Participant flow — Overall Study
MilestonePlaceboRotigotine 4 mgRotigotine 8 mg
Started827474
Completed504219
Not completed323255
Withdrew: Adverse event121733
Withdrew: Lack of efficacy774
Withdrew: Withdrawal by subject535
Withdrew: Protocol violation115
Withdrew: Non-compliance011
Withdrew: Lost to follow-up525
Withdrew: Other: subject's schedule doesn't permit100
Withdrew: Other: subject left town; family illness100
Withdrew: Other: study demands too great010
Withdrew: Other: personal family reasons001
Withdrew: Other: subject's disability per sponsor001

Outcome measures

PrimaryChange From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)

The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).

Time frame:
Baseline, Last 2 weeks of the 12-week Treatment Phase
Reported as:
Mean · Score on a scale
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)
Score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)-1.12 ± 1.83-1.27 ± 1.86-0.83 ± 1.70
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase

The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase
Reported as:
Mean · Score on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase
Score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase-14.9 ± 15.6-13.4 ± 13.7-12.8 ± 18.1
SecondaryChange From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase

Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase

No measurements were reported for this outcome.

SecondaryChange From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase

Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)

Time frame:
Baseline, Last 2 weeks of the 12-week Treatment Phase
Reported as:
Mean · Score on a scale
Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase
Score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase-0.95 ± 2.01-0.82 ± 2.03-0.48 ± 2.09
SecondaryChange From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase

General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)

Time frame:
Baseline, Last 2 weeks of the 12-week Treatment Phase
Reported as:
Mean · Score on a scale
Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase
Score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase-1.11 ± 2.05-1.19 ± 1.82-0.88 ± 2.10
SecondaryPatient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase

The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse \[score of 1\] to much better \[score of 7\]).

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase
Reported as:
Number · Patients
Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase
PatientsPlaceboRotigotine 4 mgRotigotine 8 mg
Much better8109
Moderately better14147
Mildly better251211
No change161712
Mildly worse535
Moderately worse715
Much worse112
SecondaryChange From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase

An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).

Time frame:
Baseline, Last 2 weeks of the 12-week Treatment Phase
Reported as:
Mean · Score on a scale
Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase
Score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Morning Pain Score-1.07 ± 1.91-1.30 ± 1.91-0.78 ± 1.78
Evening Pain Score-1.17 ± 1.82-1.24 ± 1.90-0.88 ± 1.89
SecondaryNumber of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase

Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.

Time frame:
12-week Treatment Phase

No measurements were reported for this outcome.

SecondaryRotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12
Time frame:
End of the Maintenance Phase/Week 12
Reported as:
Mean · ug/ML
Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12
ug/MLPlaceboRotigotine 4 mgRotigotine 8 mg
Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12—0.2388 ± 0.23370.2981 ± 0.2973
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase

The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase

No measurements were reported for this outcome.

SecondaryChange From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase

All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase

No measurements were reported for this outcome.

SecondaryChange From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase

The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.

Time frame:
Baseline, Last assessment in the 12-week Treatment Phase

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Presence of Impulse Control Disorders

Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).

Time frame:
12-week Treatment Phase

No measurements were reported for this outcome.

PrimaryChange From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)

The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).

Time frame:
Baseline, Last 2 weeks of the 12-week Treatment Phase
Reported as:
Mean · score on a scale
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)
score on a scalePlaceboRotigotine 4 mgRotigotine 8 mg
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)-1.28 ± 1.79-2.09 ± 2.07-1.57 ± 2.27

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/82 (4.9%)53/82 (64.6%)
Rotigotine 4 mg—1/73 (1.4%)55/73 (75.3%)
Rotigotine 8 mg—1/74 (1.4%)65/74 (87.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboRotigotine 4 mgRotigotine 8 mg
Chest painGeneral disorders0/821/730/74
CholelithiasisHepatobiliary disorders0/820/731/74
PneumoniaInfections and infestations1/820/730/74
Ankle fractureInjury, poisoning and procedural complications1/820/730/74
Lung injuryInjury, poisoning and procedural complications1/820/730/74
Rib fractureInjury, poisoning and procedural complications1/820/730/74
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/820/730/74
Intracranial hypotensionNervous system disorders1/820/730/74
Nerve compressionNervous system disorders1/820/730/74
Trigeminal neuralgiaNervous system disorders1/820/730/74
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboRotigotine 4 mgRotigotine 8 mg
NauseaGastrointestinal disorders18/8234/7348/74
VomitingGastrointestinal disorders1/8213/7318/74
HeadacheNervous system disorders12/8213/7312/74
Application site pruritusGeneral disorders4/823/7311/74
DizzinessNervous system disorders6/8210/738/74
SomnolenceNervous system disorders6/828/737/74
DiarrhoeaGastrointestinal disorders6/825/738/74
Upper respiratory tract infectionInfections and infestations1/827/732/74
Dry mouthGastrointestinal disorders3/825/737/74
InsomniaPsychiatric disorders4/826/737/74

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboRotigotine 4 mgRotigotine 8 mgTotal
<=18 years0000
Between 18 and 65 years817373227
>=65 years1012
Age, Continuous
Age, Continuous(years)PlaceboRotigotine 4 mgRotigotine 8 mgTotal
Mean46.4 ± 10.747.5 ± 10.347.0 ± 11.647.0 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotine 4 mgRotigotine 8 mgTotal
Female766568209
Male68620
Region of Enrollment
Region of Enrollment(participants)PlaceboRotigotine 4 mgRotigotine 8 mgTotal
United States827374229
08

Study locations

35 sites
  • Mobile, Alabama, United States
  • Mesa, Arizona, United States
  • Peoria, Arizona 85381, United States
  • Santa Ana, California 92705, United States
  • Cromwell, Connecticut 06416, United States
  • Deland, Florida 32720, United States
  • Fort Myers, Florida, United States
  • Gainesville, Florida 32611, United States
  • Ocala, Florida, United States
  • Orlando, Florida 32806, United States
  • Palm Beach, Florida, United States
  • Sunrise, Florida, United States
  • Tampa, Florida 33606, United States
  • Columbia, Maryland, United States
  • Springfield, Massachusetts 01103, United States
  • St. Louis, Missouri 63141, United States
  • Stratford, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • New York, New York 10022, United States
  • Rochester, New York, United States
  • Williamsville, New York, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina 27612, United States
  • Cleveland, Ohio 44122, United States
  • Dayton, Ohio 45408, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Portland, Oregon, United States
  • Souderton, Pennsylvania, United States
  • Crossville, Tennessee, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Bountiful, Utah, United States
  • Woodstock, Vermont 05091, United States
  • Richmond, Virginia, United States
  • Seattle, Washington 98104, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2007
First posted
Apr 24, 2007
Start
Mar 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Jan 5, 2010
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00464737
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Apr 24, 2007
Start date
Mar 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jan 5, 2010
Last update
Jun 22, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion